Abstracts Archive - Page 1719 of 2425 - ACR Meeting Abstracts

Abstract Number: 442 • 2015 ACR/ARHP Annual Meeting
Use of Adjunctive Neuroregulatory Medication to Improve Etanercept Treatment Response for Patients with Inflammatory Arthritis: A Pilot Study
Andrew Holman¹ and Edmund Ng², ¹Inmedix, Normandy Park, WA, ²Statistical Thinking, Seattle, WA
Background/Purpose: As a proposed inflammatory biomarker for autoimmune disease1,2, the autonomic nervous system (ANS) has been assessed as a predictor of anti-TNF treatment outcome3 and…
Abstract Number: 443 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Reasons for Discontinuation of Biological Disease Modifying Antirheumatic Drug in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization (RDPA) Register
Pongthorn Narongroeknawin¹, Wanruchada Katchamart², Parawee Suwannalai³, Nuntana Kasitanon⁴, Tasanee Kitumnuaypong⁵, Ajanee Mahakkanukrauh⁶ and Boonjing Siripaitoon⁷, ¹Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand, ²Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj hospital, Mahidol University, Bangkok, Thailand, ³Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁵Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital, Bangkok, Thailand, ⁶Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, ⁷Division of Rheumatology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand
Background/Purpose: To evaluate long-term efficacy and safety of biological disease modifying antirheumatic drug (bDMARD) in real-life practice and identify risk factors related to remission and drug discontinuation…
Abstract Number: 444 • 2015 ACR/ARHP Annual Meeting
TNF Inhibitor Use Across Countries in Two Time Periods Using the Meteor Database
Karen Salomon-Escoto¹, Nisha Kini¹, Sharina D. Person¹, J.A.P. da Silva², Gianfranco Ferraccioli³, T. W. J. Huizinga⁴, Robert B.M. Landewé⁵, RJ Moots⁶, D. van der Heijde⁷, Douglas J. Veale⁸, Ellen M. Gravallese¹ and Jonathan Kay¹, ¹University of Massachussets Medical School, Worcester, MA, ²Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal, ³Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ⁴Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁶Department of Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland
Background/Purpose: Biologic agents are effective treatment for rheumatoid arthritis (RA), but factors exist that may influence the prescription of these drugs in different countries. We…
Abstract Number: 445 • 2015 ACR/ARHP Annual Meeting
Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort
Arthur Lau¹, Mohammad Movahedi^2,3, Mark Tatangelo⁴, Claire Bombardier^3,5,6 and OBRI investigators, ¹Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Clinical Decision Making and Health Care, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Clinical evidence suggests concomitant treatment with a biologic Disease-Modifying Antirheumatic Drug (bDMARD) and a conventional synthetic DMARD (csDMARD), especially with methotrexate (MTX) has greater…
Abstract Number: 446 • 2015 ACR/ARHP Annual Meeting
Low Disease Activity at 12 Weeks and 24 Weeks Is Predictive of Normalized Health-Related Quality of Life in Methotrexate-Experienced Patients with Active Rheumatoid Arthritis Treated with Intravenous Golimumab Plus Methotrexate
Clifton O. Bingham III¹, Michael Weinblatt², Rene Westhovens³, Lilianne Kim⁴, Chenglong Han⁵, Stephen Xu⁴, Kim Hung Lo⁴, Kezhen L. Tang⁴, Elizabeth C. Hsia^4,6, Dennis Parenti⁷ and Shelly Kafka⁷, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³UZ Gasthuisberg, Leuven, Belgium, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Global Services, LLC, Malvern, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Previous analyses in patients (pts) with rheumatoid arthritis (RA) have evaluated the relationship between controlling disease activity and achieving long-term improvements in health-related quality…
Abstract Number: 447 • 2015 ACR/ARHP Annual Meeting
Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status
Arthur G Pratt¹, Ben Hargreaves², Dennis W Lendrem², Osman Aslam² and John D Isaacs², ¹Institute of Cellular Medicine (Musculoskeletal Research Group), National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Despite a proliferation of early arthritis (EA) clinics intended to expedite the diagnosis of rheumatoid arthritis (RA), patients continue to experience substantial and multifactorial…
Abstract Number: 448 • 2015 ACR/ARHP Annual Meeting
A Majority of Early Rheumatoid Arthritis (ERA) Patients Reach Remission By 6 Months in Usual Rheumatology Care
Tuomas Rannio¹, Juha Asikainen², Pekka Hannonen³, Timo Yli-Kerttula⁴, Päivi Ekman⁵, Laura Pirilä⁶, Markku Mali⁷, Laura Kuusela⁷, Maija Puurtinen-Vilkki⁷, Saara Kortelainen⁸, Johanna Paltta⁷, Kirsi Taimen⁷, Heidi Mäkinen⁹, Pia Isomäki⁹, Terhi Uotila⁹, Markku J. Kauppi¹⁰, Kari Laiho¹¹, Satu Nyrhinen¹¹, Tuulikki Sokka-Isler¹ and FIN-ERA study group, ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyväskylä Central Hospital, Jyväskylä, Finland, ³Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁴Sairaalantie 3, Central Hospital of Satakunta, Pori, Finland, ⁵Central Hospital of Satakunta, Pori, Finland, ⁶Tyks, P.O. Box 52, Turku University Central Hospital, Turku, Finland, ⁷Turku University Central Hospital, Turku, Finland, ⁸Alvar Aallontie 275, Turku University Central Hospital, Turku, Finland, ⁹Tampere University Hospital, Tampere, Finland, ¹⁰Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ¹¹Päijät-Häme Central Hospital, Lahti, Finland
Background/Purpose: Finnish national combination treatment trials have demonstrated excellent outcomes in patients with ERA including 90% of patients reaching DAS28 remission at 6 months. Whether…
Abstract Number: 449 • 2015 ACR/ARHP Annual Meeting
Change from SC to IV Abatacept and Back in Patients with Rheumatoid Arthritis As Simulation of a Vacation: A Prospective Phase IV, Open Label Trial (A-BREAK)
Ruediger Mueller¹, Michael Gengenbacher², Symi richter³, Jean Dudler⁴, Burkhard Moeller⁵ and Johannes von Kempis⁶, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Bethesdaspital, Basel, Switzerland, ³Bethsdaspital, Basel, Switzerland, ⁴Kantonsspital Fribourg, Fribourg, Switzerland, ⁵Rheumatology, Inselspital-University Hospital, Bern, Switzerland, ⁶Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Holiday seasons can present a major problem to RA patients treated with weekly subcutaneous biologics, including subcutaneous (SC) abatacept. Therefore an evaluation of the…
Abstract Number: 450 • 2015 ACR/ARHP Annual Meeting
Use of Tofacitinib in a Real World Setting: Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: It is well accepted that patients studied in pharmaceutically sponsored clinical trials do not always represent the types of patients seen in clinical practice. …
Abstract Number: 451 • 2015 ACR/ARHP Annual Meeting
Efficacy of Tofacitinib in a Real World Setting Using the Database Jointman
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: Tofacitinib (TFA) was approved for the treatment of rheumatoid arthritis (RA) in November of 2012. It is well accepted that patients studied in pharmaceutically…
Abstract Number: 452 • 2015 ACR/ARHP Annual Meeting
Associations Between Arthritis Patient, Disease-Specific and Provider Characteristics and Medication Information Source Use
Lorie Geryk¹, Susan J. Blalock², Robert DeVellis³, Joanne M. Jordan³ and Delesha Carpenter⁴, ¹Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, ²Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ⁴Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Asheville, NC
Background/Purpose: Few studies have described how patient, disease-specific, and provider factors are associated with medication information source use among arthritis patients. We address this research…
Abstract Number: 453 • 2015 ACR/ARHP Annual Meeting
Highly Elevated Rheumatoid Factor Is a Risk Factor for Abatacept Treatment Failure in Japanese Patients with Rheumatoid Arthritis
Shunya Kaneshita¹, Chisun Min¹, Omata Fumio², Masei Suda¹, Ryo Rokutanda¹, Hisanori Shimizu³, Tokutaro Tsuda¹, MItsumasa kishimoto⁴, Ken-ichi Yamaguchi³ and Masato Okada³, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Center for Clinical Epidemiology, St.Luke' International Hospital and St. Luke's Life Science Institute, Tokyo, Japan, ³Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁴St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: It is valuable to predict the effectiveness of biologics in the patients with rheumatoid arthritis (RA) to avoid unnecessary side effects and to save…
Abstract Number: 454 • 2015 ACR/ARHP Annual Meeting
No Sex Bias in the Escalation of Therapy in the Treatment of Early Inflammatory Arthritis
Stephanie Garner¹, Cheryl Barnabe², Gilles Boire³, Carol Hitchon⁴, Edward C. Keystone⁵, Boulos Haraoui⁶, J Carter Thorne⁷, Diane Tin⁸, Janet E. Pope⁹, VP Bykerk¹⁰ and CATCH Investigators, ¹University of Calgary, Calgary, AB, Canada, ²Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁵Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Institut de Rhumatologie, Montreal, QC, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹University of Western Ontario, London, ON, Canada, ¹⁰Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Several studies have shown that females with early inflammatory arthritis have higher disease activity, worse functional impairment and worse patient-reported outcomes but do not…
Abstract Number: 455 • 2015 ACR/ARHP Annual Meeting
Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care
Janet E. Pope¹, Emmanouil Rampakakis² and John S. Sampalis³, ¹University of Western Ontario, London, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Clinical Research, JSS Medical Research, Westmount, QC, Canada
Background/Purpose: Treatment sustainability can measure drug effectiveness and encompasses drug effectiveness, safety, and compliance. Recent data suggest that differences in retention may exist between biologic…
Abstract Number: 456 • 2015 ACR/ARHP Annual Meeting
Disease and Treatment Characteristics That Might Influence Long-Term Retention with Biologics in the Real-World Clinical Setting: Experience from the Rhumadata Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui³, Jean-Pierre Raynauld¹, Diane Sauvageau¹, Angèle Turcotte⁴, Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Institut de Rhumatologie, Montreal, QC, Canada, ⁴Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada
Disease and Treatment Characteristics that Might Influence Long-term Retention with Biologics in the Real-world Clinical Setting: Experience from the Rhumadata Clinical Database and Registry Background/Purpose:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].